跳至主要内容
临床试验/NL-OMON48239
NL-OMON48239招募中2 期

Cardiac CT for therapeutic stratification in low gradient presumed severe aortic stenosis with preserved left ventricular ejection fraction - CAPTURE AS

OLVG0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Written informed consent
  • 2. Echocardiographic severe aortic valve stenosis with aortic valve area <1.0
  • 3. Preserved left ventricular ejection fraction (LVEF), defined as LVEF at
  • 4. Low mean transvalvular aortic pressure gradiënt (<40 mmHg)
  • 5. Age at least 60 years
  • 6. Patient has suitable anatomy to allow transcatheter aortic valve implantation
  • 7. Patient demonstrates symptoms suspicious of heart failure or severe aortic
  • valve stenosis

排除标准

  • 1.Hypersensitivity or contraindication to aspirin, heparin, clopidogrel or
  • sensitivity for contrast media which cannot be adequately pre-medicated
  • 2.Blood dyscrasias as defined: leukopenia (WBC <1000 mm3), thrombocytopenia
  • (platelet count <50,000 cells/mm3), history of bleeding diathesis or
  • coagulopathy
  • 3.Concomitant valvular disease, defined as more than moderate aortic valve
  • regurgitation, and/or more than moderate mitral valve regurgitation and/or
  • 4.Ongoing sepsis, including active endocarditis
  • 5.Symptomatic carotid or vertebral artery disease or successful treatment of
  • carotid stenosis within 6 weeks of inclusion
  • 6.Active gastrointestinal (GI) bleeding within the past 3 months
  • 7.Subject refuses blood transfustion
  • 8.Severe dementia
  • 9.Estimated life expectancy of less than 24 months due to associated
  • non-cardiac comorbidities
  • 10.Other medical, social, or psychological conditions that in the opinion of
  • the investigator precludes the subject form appropriate consent or adherence to
  • the protocol required follow-up exams
  • 11.Reduced LV function (LVEF <50%)
  • 12.Native aortic annulus size <18 mm or >30 mm per baseline diagnostic imaging
  • 13.sinus of valsalva diameter <25 mm or sinus of valsalva height <15 mm
  • 14.Concomitant planned coronary artery bypass graft or additional valve
  • intervention
  • 15.Hypertrophic obstructive cardiomyopathy
  • 16.Echocardiographic or CT evidence of intracardiac mass, thrombus or vegetation
  • 17.Transarterial access not able to accommodate an 18Fr sheath
  • 18.Patient not being able to exercise or perform 6 MWT

研究者

发起方
OLVG

相似试验